1,828 research outputs found
Recommended from our members
A Label-Free Platform for Identification of Exosomes from Different Sources.
Exosomes contain cell- and cell-state-specific cargos of proteins, lipids, and nucleic acids and play significant roles in cell signaling and cell-cell communication. Current research into exosome-based biomarkers has relied largely on analyzing candidate biomarkers, i.e., specific proteins or nucleic acids. However, this approach may miss important biomarkers that are yet to be identified. Alternative approaches are to analyze the entire exosome system, either by "omics" methods or by techniques that provide "fingerprints" of the system without identifying each individual biomolecule component. Here, we describe a platform of the latter type, which is based on surface-enhanced Raman spectroscopy (SERS) in combination with multivariate analysis, and demonstrate the utility of this platform for analyzing exosomes derived from different biological sources. First, we examined whether this analysis could use exosomes isolated from fetal bovine serum using a simple, commercially available isolation kit or necessitates the higher purity achieved by the "gold standard" ultracentrifugation/filtration procedure. Our data demonstrate that the latter method is required for this type of analysis. Having established this requirement, we rigorously analyzed the Raman spectral signature of individual exosomes using a unique, hybrid SERS substrate made of a graphene-covered Au surface containing a quasi-periodic array of pyramids. To examine the source of the Raman signal, we used Raman mapping of low and high spatial resolution combined with morphological identification of exosomes by scanning electron microscopy. Both approaches suggested that the spectra were collected from single exosomes. Finally, we demonstrate for the first time that our platform can distinguish among exosomes from different biological sources based on their Raman signature, a promising approach for developing exosome-based fingerprinting. Our study serves as a solid technological foundation for future exploration of the roles of exosomes in various biological processes and their use as biomarkers for disease diagnosis and treatment monitoring
Comparison of Supervised Classification Methods for Protein Profiling in Cancer Diagnosis
A key challenge in clinical proteomics of cancer is the identification of biomarkers that could allow detection, diagnosis and prognosis of the diseases. Recent advances in mass spectrometry and proteomic instrumentations offer unique chance to rapidly identify these markers. These advances pose considerable challenges, similar to those created by microarray-based investigation, for the discovery of pattern of markers from high-dimensional data, specific to each pathologic state (e.g. normal vs cancer). We propose a three-step strategy to select important markers from high-dimensional mass spectrometry data using surface enhanced laser desorption/ionization (SELDI) technology. The first two steps are the selection of the most discriminating biomarkers with a construction of different classifiers. Finally, we compare and validate their performance and robustness using different supervised classification methods such as Support Vector Machine, Linear Discriminant Analysis, Quadratic Discriminant Analysis, Neural Networks, Classification Trees and Boosting Trees. We show that the proposed method is suitable for analysing high-throughput proteomics data and that the combination of logistic regression and Linear Discriminant Analysis outperform other methods tested
Genomic and proteomic analysis with dynamically growing self organising tree (DGSOT) for measuring clinical outcomes of cancer
Genomics and proteomics microarray technologies are used for analysing molecular and cellular expressions of cancer. This creates a challenge for analysis and interpretation of the data generated as it is produced in large volumes. The current review describes a combined system for genetic, molecular interpretation and analysis of genomics and proteomics technologies that offers a wide range of interpreted results. Artificial neural network systems technology has the type of programmes to best deal with these large volumes of analytical data. The artificial system to be recommended here is to be determined from the analysis and selection of the best of different available technologies currently being used or reviewed for microarray data analysis. The system proposed here is a tree structure, a new hierarchical clustering algorithm called a dynamically growing self-organizing tree (DGSOT) algorithm, which overcomes drawbacks of traditional hierarchical clustering algorithms. The DGSOT algorithm combines horizontal and vertical growth to construct a mutlifurcating hierarchical tree from top to bottom to cluster the data. They are designed to combine the strengths of Neural Networks (NN), which have speed and robustness to noise, and hierarchical clustering tree structure which are minimum prior requirement for number of clusters specification and training in order to output results of interpretable biological context. The combined system will generate an output of biological interpretation of expression profiles associated with diagnosis of disease (including early detection, molecular classification and staging), metastasis (spread of the disease to non-adjacent organs and/or tissues), prognosis (predicting clinical outcome) and response to treatment; it also gives possible therapeutic options ranking them according to their benefits for the patient.Key words: Genomics, proteomics, microarray, dynamically growing self-organizing tree (DGSOT)
Metabolomics for mitochondrial and cancer studies
AbstractMetabolomics, a high-throughput global metabolite analysis, is a burgeoning field, and in recent times has shown substantial evidence to support its emerging role in cancer diagnosis, cancer recurrence, and prognosis, as well as its impact in identifying novel cancer biomarkers and developing cancer therapeutics. Newly evolving advances in disease diagnostics and therapy will further facilitate future growth in the field of metabolomics, especially in cancer, where there is a dire need for sensitive and more affordable diagnostic tools and an urgency to develop effective therapies and identify reliable biomarkers to predict accurately the response to a therapy. Here, we review the application of metabolomics in cancer and mitochondrial studies and its role in enabling the understanding of altered metabolism and malignant transformation during cancer growth and metastasis. The recent developments in the area of metabolic flux analysis may help to close the gap between clinical metabolomics research and the development of cancer metabolome. In the era of personalized medicine with more and more patient specific targeted therapies being used, we need reliable, dynamic, faster, and yet sensitive biomarkers both to track the disease and to develop and evolve therapies during the course of treatment. Recent advances in metabolomics along with the novel strategies to analyze, understand, and construct the metabolic pathways opens this window of opportunity in a very cost-effective manner. This article is part of a Special Issue entitled: Bioenergetics of Cancer
NMR-based metabolomics of biofluids in cancer
Author's accepted version (post-print).Available from 20/04/2019.acceptedVersio
Bioinformatics tools for cancer metabolomics
It is well known that significant metabolic change take place as cells are transformed from normal to malignant. This review focuses on the use of different bioinformatics tools in cancer metabolomics studies. The article begins by describing different metabolomics technologies and data generation techniques. Overview of the data pre-processing techniques is provided and multivariate data analysis techniques are discussed and illustrated with case studies, including principal component analysis, clustering techniques, self-organizing maps, partial least squares, and discriminant function analysis. Also included is a discussion of available software packages
Oncoproteomics: Opportunities, Challenges & Advanced Technologies
Oncoproteomics is nothing but the analysis of proteins and their interactions in a cancer cell through proteomic technologies. Oncoproteomics is playing a progressively significant part in diagnosis and the management of cancer. It also helps in the advancement of personalized therapy of cancer. Oncoproteomics holds great potential not only for opening the complicated molecular episodes of tumorigenesis but also for those that regulate clinically essential tumor habits, like metastasis, invasion, and resistance to treatment. Protein molecules show a significant impact on the evolution of cancer as it mainly develops due to abnormal signaling pathways. Detection and comprehension of these alterations is the major concept of oncoproteomics. Novel proteomic technologies related to cancer are defined in short, which are assisting not only in the comprehension of the mechanism of drug-resistant in cancer but also bestow some guides in management. For the diagnostic and prognostic categorization of the disease condition, and in measuring the drug efficiency and toxicity acclimatization of proteomic technologies in clinical laboratories is the fundamental objective of oncoproteomics. A considerable influence on the management of cancer patients and on a spectacular revolution in cancer research might notice by data obtained through such novel technologies. For the cancer therapy, the identification of novel targets, as well as an understanding of tumor development, might permit by the research of tumor-specific proteomic profiles. A wide perspective on drug-resistant and anticancer drug discovery, proteomic biomarkers and its function in the diagnosis of cancer, current innovation in proteomic technologies have tried to give in this review
Novel urinary and serological markers of prostate cancer using proteomics techniques: an important tool for early cancer diagnosis and treatment monitoring
In Africa, Prostate cancer (PCa) is the most frequently diagnosed solid organ tumour in males and use of prostate specific antigen (PSA) is presently fraught with diagnostic inaccuracies. Not least, in a multi-ethnic society like South Africa, proteome differences between African, Caucasian and Mixed-Ancestry PCa patients are largely unknown. Hence, discovery and validation of affordable, non-invasive and reliable diagnostic biomarkers of PCa would expand the frontiers of PCa management. We have employed two high-throughput proteomics technologies to identify novel urine- and blood-based biomarkers for early diagnosis and treatment monitoring of prostate cancer in a South African cohort as well as elucidate proteome differences in patients from our heterogeneous cohort. We compared the urinary proteomes of PCa, Benign Prostatic Hyperplasia (BPH), disease controls comprising patients with other uropathies (DC) and normal healthy controls (NC) both by pooling and individual discovery shotgun proteomic assessment on a nano-Liquid chromatography (nLC) coupled Hybrid Quadrupole-Orbitrap Mass Spectrometer platform. In-silico verification of identified biomarkers was performed using the Human Protein Atlas (HPA) as well as SRMAtlas; and verified potential biomarkers were experimentally prevalidated using a targeted parallel reaction monitoring (PRM) proteomics approach. Further, we employed the CT100+ antigen microarray platform to assess the differential humoral antibody response of PCa, DC and BPH patients in our cohort to a panel of 123 tumour-associated cancer antigens. Candidate antigen biomarkers were analyzed for ethnic group variation in our cohort and potential cancer diagnostic and immunotherapeutic inferences were drawn. Using these approaches, we identified 5595 and 9991 non-redundant peptides from the pooled and individual experiments respectively. While nine proteins demonstrated ethnic trend, 37 and 73 proteins were differentially expressed by pooled and individual analysis respectively. All 32 verified biomarkers were prevalidated with parallel reaction monitoring. Good PRM signals for 12 top ranking biomarker was observed, including PSA and prostatic acid phosphatase. We also identified 41 potential diagnostic and immunotherapeutic antigen biomarkers. Proteogenomic functional pathway analyses of differentially expressed antigens showed similar enrichments of biologic processes. We identified herein novel urinary and blood-based potential diagnostic biomarkers and immunotherapeutic targets of PCa in a South African PCa Cohort using multiple proteomics approaches
Recommended from our members
Proteomic analysis of biomarkers associated with immunotherapy in murine tumour models
Emergence of proteomics and high-throughput technologies has allowed the identification of protein expression patterns of disease that potentially hold clinical importance in predictive medicine. The analysis of complex data generated by these technologies incorporates the use of computer algorithms for data mining and identification of important protein biomarkers. Such candidate biomarkers can potentially be used for diagnosis, prognosis and monitoring a variety of diseases as well as the prediction of therapy response. Mass spectrometry has been used widely, for the discovery and quantitation of disease associated biomarkers using a variety of samples such as serum and tissue. In particular, matrix assisted laser desorption/ionisation time of flight mass spectrometry (MALDI-TOF MS) has been used to generate proteomic profiles or “fingerprints” from serum to distinguish patients at different clinical stages of disease. Currently, early stage disease is difficult to diagnose in most cancers as current cancer markers have limited sensitivity and specificity. In advanced stage metastatic disease, treatment options are limited, although it is recognised that some patients may benefit from immunotherapy and in particular vaccine therapy. The use of animal models is critical to evaluate the efficacy of immunotherapies and to investigate tumour immunity in general and the mechanisms involved in tumour progression. These models provide an in vivo environment which cannot be reproduced in vitro, which results in more accurate and reliable information on the host response to immunotherapy and the mechanisms involved
- …